Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Primatene Mist CRL Underscores Challenges For OTC Asthma Treatments

Executive Summary

Second FDA complete response letter for a reformulated Primatene Mist likely pushes back by another 18 months Amphastar's potential relaunch of the OTC product after satisfying the US agency's concerns about consumers correcting using the product without a doctor’s intervention.

Advertisement

Related Content

OTC Primatene Mist Returns: Market Future Bright After Cloudy NDA History
OTC Primatene Mist Returns: Market Future Bright After Cloudy NDA History
Primatene Mist NDA Expected By July After FDA OKs OTC Asthma Inhaler Trial
Primatene Mist NDA Expected By July After FDA OKs OTC Asthma Inhaler Trial
Exclusivity Provision Surfaces In OTC Monograph Bill
Exclusivity Provision Surfaces In OTC Monograph Bill
Keeping Track: CDER 2016 Novel Approvals Hold At 22 As US FDA Declines Cempra's Solithera
Dry Powder Blows Dr. Natural OTC Epinephrine Inhaler Out Of Compliance
Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook
FDA Panel Votes Against Primatene Reboot Due To Safety Concerns

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119762

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel